Press release3/31/2026, 6:00 AMNovakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors
Press release3/2/2026, 6:00 AMNovakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting
Press release2/25/2026, 3:45 PMThe board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines
Press release2/12/2026, 4:45 PMNovakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines
Press release2/6/2026, 7:00 AMNovakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover
Regulatory press release12/22/2025, 7:00 AMNovakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover
Regulatory press release11/21/2025, 7:00 AMInterim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851
Press release10/9/2025, 7:00 AMNovakand Pharma provides an update on the ongoing reverse take over process
Regulatory press release9/23/2025, 1:00 PMPeter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board
Regulatory press release9/18/2025, 4:00 PMKancera initiates process to seek stakeholders for a reverse take over
Regulatory press release8/28/2025, 6:00 AMInterim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851
Press release6/16/2025, 6:30 AMKancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145
Regulatory press release6/13/2025, 6:00 AMKancera reports positive top-line results from the KANDOVA study
Regulatory press release6/5/2025, 6:00 AMKancera reports positive outcome of pre-IND meeting with FDA
Regulatory press release5/23/2025, 6:00 AMInterim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851
Press release5/20/2025, 6:30 AMKancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program